基于智能体模型评估阿尔伯塔省孕妇百日咳免疫接种的效果:一项加拿大免疫研究网络研究
该研究开发并验证了一个智能体模型,用以刻画阿尔伯塔省百日咳流行病学特征,评估孕妇百日咳疫苗接种的项目效果(PVE)与人群可预防分数(PFP)。模型预测孕妇接种可显著减少婴儿百日咳病例,免疫钝化会轻微削弱效果,模型对孕妇疫苗覆盖率最敏感,暴露途径中断发挥一定作用。
要点
- 孕妇疫苗覆盖率50%时,PVE为87%(95%分位数82-91%),PFP为44%(95%分位数41-45%)。
- 覆盖率75%时,PVE为90%(95%分位数86-92%),PFP为68%(95%分位数65-69%)。
- 因暴露途径中断所致的PVE为54-57%,免疫钝化会轻微削弱疫苗效果。
核心结论
- 模型预测孕妇接种可显著减少婴儿未来百日咳病例,免疫钝化会轻微削弱其效果。
- 模型对孕妇疫苗覆盖率最敏感,暴露途径中断在减少婴儿百日咳负担中发挥作用。
- 孕妇免疫对婴儿以外人群的效果仍有待阐明。
研究设计与样本
- 研究开发并验证了一个智能体模型,用以刻画阿尔伯塔省百日咳流行病学特征。
- 研究计算了孕妇百日咳疫苗接种的项目效果(PVE)与人群可预防分数(PFP),并模拟了免疫钝化和暴露途径中断的作用。
主要发现
- 在大多数模拟中,PVE与孕妇免疫被动免疫持续时间呈负相关。
- 孕妇疫苗覆盖率50%时,PVE为87%(95%分位数82-91%),PFP为44%(95%分位数41-45%)。
- 月龄0-2、2-4、4-6和6-12个月间隔,PVE范围82%-99%,PFP范围41%-49%。
- 覆盖率75%时,PVE为90%(95%分位数86-92%),PFP为68%(95%分位数65-69%)。
- 覆盖率50%且钝化10%时,PVE为86%(95%分位数77-87%),PFP为43%(95%分位数39-44%);钝化50%时,PVE为76%(95%分位数70-81%),PFP为38%(95%分位数35-40%)。
关键数值与推荐
- 孕妇疫苗覆盖率50%时,PVE为87%(95%分位数82-91%),PFP为44%(95%分位数41-45%)。
- 孕妇疫苗覆盖率75%时,PVE为90%(95%分位数86-92%),PFP为68%(95%分位数65-69%)。
- 月龄0-2、2-4、4-6和6-12个月间隔,PVE范围82%-99%,PFP范围41%-49%。
- 覆盖率50%且钝化10%时,PVE为86%(95%分位数77-87%),PFP为43%(95%分位数39-44%)。
- 覆盖率50%且钝化50%时,PVE为76%(95%分位数70-81%),PFP为38%(95%分位数35-40%)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 孕妇免疫对婴儿以外人群的效果仍有待阐明。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: The re-emergence of pertussis has occurred in the past two decades in developed countries. The highest morbidity and mortality is seen among infants. Vaccination in pregnancy is recommended to reduce the pertussis burden in infants. METHODS: We developed and validated an agent-based model to characterize pertussis epidemiology in Alberta. We computed programmatic effectiveness of pertussis vaccination during pregnancy (PVE) in relation to maternal vaccine coverage and pertussis disease reporting thresholds. We estimated the population preventable fraction (PFP) of different levels of maternal vaccine coverage against counterfactual "no-vaccination" scenario. We modeled the effect of immunological blunting and measured protection through interruption of exposure pathways. RESULTS: PVE was inversely related to duration of passive immunity from maternal immunization across most simulations. In the scenario of 50% maternal vaccine coverage, PVE was 87% (95% quantiles 82-91%), with PFP of 44% (95% quantiles 41-45%). For monthly age intervals of 0-2, 2-4, 4-6 and 6-12, PVE ranged between 82 and 99%, and PFP ranged between 41 and 49%. At 75% maternal vaccine coverage, PVE and PFP were 90% (95% quantiles 86-92%) and 68% (95% quantiles 65-69%), respectively. At 50% maternal vaccine coverage and 10% blunting, PVE and PFP were 86% (95% quantiles 77-87%) and 43% (95% quantiles 39-44%), respectively, while at 50% blunting, the corresponding values of PVE and PFP were 76% (95% quantiles 70-81%) and 38% (95% quantiles 35-40%). PVE attributable to interruption of exposure pathways was 54-57%. CONCLUSIONS: Our model predicts significant reduction in future pertussis cases in infants due to maternal vaccination, with immunological blunting slightly moderating its effectiveness. The model is most sensitive to maternal vaccination coverage. The interruption of exposure pathways plays a role in the reduction of pertussis burden in infants due to maternal immunization. The effect of maternal immunization on population other than infants remains to be elucidated.
引用
- Hempel K, McDonald W, Osgood ND, et al. Evaluation of the effectiveness of maternal immunization against pertussis in Alberta using agent-based modeling: A Canadian immunization research network study. Vaccine. 2023. PMID: 36775775. doi:10.1016/j.vaccine.2022.12.071
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。